短程大剂量盐酸米托蒽醌与阿糖胞苷治疗难治复发急性白血病的临床研究

CLINICAL STUDY ON SHORT COURSE HIGH DOSE MITOXANTRONE AND CYTOSINE ARABINOSIDE FOR TREATMENT IN REFRACTORY AND RELAPSED ACUTE LEUKEMIA

目的 :评价大剂量盐酸米托蒽醌 40 mg/ m2单剂与阿糖胞苷 (1～ 1.5 ) g/ m2连用 5 d,治疗难治复发急性白血病的疗效及推广应用价值。方法 :以该方案对 2 0例难治复发急性白血病进行 2 2例次治疗。结果 :2 2例次治疗中的 2 0例次获得完全缓解 (CR90 .9% ) ,1例次取得部分缓解 (PR4.5 4% ) ,其中 14例急淋的 16例次治疗 ,14例次取得完全缓得 ,1例次部分缓解 ,1例无效 ,6例急性粒细胞白血病治疗均取得完全缓解 ,无治疗相关死亡。结论 :短程大剂量米托蒽醌联合阿糖胞苷对难治复发急性白血病有较高的疗效 ,可提高缓解率 ,降低死亡率。

Objective:A clinical study was conducted in order to evaluate therapetic effect and clinical implication by short course high dose mitoxantrone 40 mg/m 2 on day 2 and Ara C (cytosar)1 g/m 2 1.5 g/m 2 daily for five days in refractory and relapsed acute leukemia.Methods:Twenty patients with refractory and relapsed acute leukemia received twenty two treatment course therapy.Results:Twenty of twenty two treatment course achieved complete remission (CR 90.9%),one treatment course partial remission(PR 4.54%).including 14 of 16 treatment course treatment on fourteen patients with ALL and 6 treatment course on six patients with AML achived complete remission.No death occured during the protocol therapy.Conclusion:Short course high dose mitoxantrone with Ara C demonstrated a higher CR,lower mortality rate and can be applied in the treatment of refractory and relapsed acute leukemia.